Moxifloxacin · Avelox, Avelox In Sodium Chloride 0.8% In Plastic Container

What is Moxifloxacin?

Moxifloxacin is a fluoroquinolone anti-infective that binds and inhibits bacterial DNA gyrase and topoisomerase IV, blocking DNA replication and repair and leading to death of susceptible bacteria.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Avelox, Avelox In Sodium Chloride 0.8% In Plastic Container, Vigamox, Positive Control

Drug type

Small molecule

Targets

DNA gyrase, topoisomerase IV

Mechanism

Inhibitor of DNA gyrase and topoisomerase IV

Pathways

bacterial DNA replication, bacterial DNA repair

Therapy area

Infectious disease

Developer

Bayer Pharms

In trials of

ACHV, ALMS, AMGN, ANTX, AVIR, CNTB, CORT, CYTK, ENTA, INVA

FDA status

Approved as Avelox, Avelox In Sodium Chloride 0.8% In Plastic Container, Vigamox (April 27, 2001), NDA021334 · FDA label

✅ FDA-approved uses

• Bacterial conjunctivitis (Vigamox)

From the indications section of the FDA label (version of Jan 22, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Mycobacterium Abscessus InfectionMycobacterium Abscessus Pulmonary DiseaseNon-Tuberculous Mycobacteria Pulmonary DiseaseNon-Tuberculous Mycobacterial (NTM) InfectionsAutoimmune DiseasesHealthyHealthy VolunteerHealthy Volunteer StudyObesityOverweightQT IntervalQT Intervals ChangesQTc IntervalQTc Intervals Changes

Sources

• FDA label (DailyMed)
• FDA label Vigamox (2026-01-22), indications
• NCI Thesaurus
• ClinicalTrials.gov NCT02155205
• ClinicalTrials.gov NCT04175808
• ClinicalTrials.gov NCT04238195
• ClinicalTrials.gov NCT04795479

Updated Oct 11, 2026.